617 filings
Page 5 of 31
8-K
7e3yzmetiz2dc4f
26 Dec 19
Form of Securities Purchase Agreement
8:46am
424B5
68pz17j8n deel0ohp0
23 Dec 19
Prospectus supplement for primary offering
7:39am
8-K
fhef11b zt1u
9 Dec 19
Other Events
8:15am
8-K
w4k9r0a
12 Nov 19
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
7:39am
8-K
e2avoq4j zcm
28 Oct 19
Umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports TG plans to present the data at a future medical conference and discuss the results with the FDA
7:59am
8-K
qttaxhb2wy9uem1ur6z
12 Sep 19
Other Events
9:25am
S-3ASR
nvh o2122m
5 Sep 19
Automatic shelf registration
4:17pm
RW
ugfeqr jlsta2
5 Sep 19
Registration withdrawal request
4:00pm
8-K
pzmyyvftc 44615bij
9 Aug 19
Results of Operations and Financial Condition
7:33am
8-K
c6m9jp b2
13 Jun 19
Submission of Matters to a Vote of Security Holders
4:07pm
PX14A6G
5bypt9h
31 May 19
Letter to shareholders
2:48pm
8-K
i6kz8jj8wmv uzzgznf4
10 May 19
TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
7:01am
8-K
x53kbb6t5sg1258i3v
8 May 19
Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks
12:00am
DEFA14A
4pes6
30 Apr 19
Additional proxy soliciting materials
4:35pm